GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine
Combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early...
immunotherapy
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative...
Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum
Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential...
Spexis provides business update and announces financial results for the first half of 2023
Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of...
Medicenna Announces Results of Annual and Special Meeting of Shareholders
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage...
Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition
Positive Conclusion Reached in Immunomodulator I Patent OppositionPatent opposition hearing cancelledLONDON, UK / ACCESSWIRE / September 29, 2023 / Poolbeg...
IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer
Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS...
GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564
Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development GIGA-564 is a differentiated anti-CTLA4 antibody with potential...
Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication
Evidence from multiple researchers supports Vigil enhancement of clonal neoantigen effector cell response and correlation to relapse free survival and...
Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a...
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersThe...
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...
T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN FRANCISCO and BERLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing...
Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting
Abstract titles to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting were released publicly today at...
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials...
SIRPant Immunotherapeutics to Present Trial in Progress Poster at the Society for Immunotherapy of Cancer 38th Annual Meeting
HUMMELSTOWN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based...
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meetingCompany to present interim...
Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein
Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the...
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be...